Research methodology: Evaluating complementary and alternative therapies

Drug Information Journal

Volumn 36, Issue 3, 2002, Pages 535-548

  Tamayo, Carmen ^a   Boon, Heather ^a   Ghishan, Fayez ^a   Trinh, Kien ^a  

^a Foresight Links Corporation   (Canada)

Author keywords

Alternative medicine; Clinical trials; Complementary therapies; Methods; Research methodology

Indexed keywords

DRUG; HERBACEOUS AGENT;

ACUPUNCTURE; ADULT; ALTERNATIVE MEDICINE; CLINICAL TRIAL; CONSUMER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; DRUG INDUSTRY; DRUG RESEARCH; FINANCIAL MANAGEMENT; GOVERNMENT; HEALTH CARE QUALITY; HERBAL MEDICINE; HUMAN; MARKETING; METHODOLOGY; PATIENT CARE; PEDIATRICS; PRIORITY JOURNAL; PUBLICATION; RELIABILITY; REVIEW; SAFETY; TREATMENT OUTCOME; UNIVERSITY;

EID: 0036383963     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150203600308     Document Type: Review

References (72)

1. Malik IA, Khan NA, Khan W. Use of unconventional methods of therapy by cancer patients in Pakistan. Eur J Epidemiol. 2000;16(2):155-160.
2. Wootton JC, Sparber A. Surveys of complementary and alternative medicine: part I. General trends and demographic groups. J Altern Complement Med. 2001;7(2):195-208.
3. Thomas KJ, Nicholl JP, Coleman P. Use and expenditure on complementary medicine in England: a population based survey. Complement Ther Med. 2001; 9(1):2-11.
4. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al. Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. JAMA. 1998; 280(18):1569-1575.
5. Fisher P, Ward A. Complementary medicine in Europe. Br Med J. 1994;309(6947):107-111.
6. MacLennan AH, Wilson DH, Taylor AW. Prevalence and cost of alternative medicine in Australia. Lancet. 1996; 347(9001):569-573.
7. Archer C. Research issues in complementary therapies. Complement Ther Nurs Midwifery. 1999;5(4): 108-114.
8. Astin JA, Marie A, Pelletier KR, Hansen E, Haskell WL. A review of the incorporation of complementary and alternative medicine by mainstream physicians. Arch Intern Med. 1998;158(21):2303-2310.
9. Kessler RC, Davis RB, Foster DF, Van Rompay MI, Walters EE, Wilkey SA, et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med. 2001; 135(4):262-268.
10. Ernst E. Research into complementary/alternative medicine: an attempt to dispel the myths. Int J Clin Pract. 2001;55(6):376-379.
11. Mills SY. The House of Lords report on complementary medicine: a summary. Complement Ther Med. 2001;9(1):34-39.
12. Nahin RL, Straus SE. Research into complementary and alternative medicine: problems and potential. Br Med J. 2001;20;322(7279):161-164.
13. Muscat M. Straus gives state of the center, CAM on PUBMED unveiled. Altern Ther Health Med. 2001; 7(2):23-26.
14. Bensoussan A. Complementary medicine. Searching for the evidence. Aust Fam Physician. 2000;29(12): 1129-1133
15. Vickers A. Recent advances: complementary medicine. Br Med J. 2000;321(7262):683-686.
16. Dougherty K, Touger-Decker R, O' Sullivan MJ. Personal and professional beliefs and practices regarding herbal medicine among the full time faculty of the Newark-based schools of the University of Medicine and Dentistry of New Jersey. Integrative Med. 2000;2(2):57-64.
17. Haynes B. Can it work? Does it work? Is it worth it? The testing of healthcare interventions is evolving. Br Med J. 1999;319(7211):652-653.
18. Barnes J, Abbot NC, Harkness EF, Ernst E. Articles on complementary medicine in the mainstream medical literature: an investigation of MEDLINE, 1966 through 1996. Arch Intern Med. 1999;159(15): 1721-1725.
19. Vickers AJ. Bibliometric analysis of randomised controlled trials in complementary medicine. Complement Ther Med. 1998;(6):185-189.
20. Eisenberg DM, et al. Unconventional Medicine in the United States: Prevalence, Cost, Patterns of Usage. New Engl J Med. 1993;328:246-252
21. Beyerstein BL. Alternative medicine and common errors of reasoning. Acad Med. 2001;76(3):230-237.
22. Bostrom H. Placebo-the forgotten drug. Scand J Work Environ Health. 1997;23 Suppl 3:53-57.
23. Vickers A. Methodological issues in complementary and alternative medicine research: a personal reflection on 10 years of debate in the United Kingdom. J Altern Complement Med. 1996;2(4):515-524.
24. Levin JS, Glass TA, Kushi LH, Schuck JR, Steele L, Jonas WB. Quantitative methods in research on complementary and alternative medicine. A methodological manifesto. NIH Office of Alternative Medicine. Med Care. 1997;35(11):1079-1094.
25. Enkin MW, Jadad AR. Using anecdotal information in evidence-based health care: heresy or necessity? Ann Oncol. 1998;9(9):963-966.
26. Redelmeier DA, Rozin P, Kahneman D. Understanding patients' decisions. Cognitive and emotional perspectives. JAMA. 1993;270(1):72-76.
27. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342(25):1878-1886.
28. Gill P, Dowell AC, Neal RD, Smith N, Heywood P, Wilson AE. Evidence based general practice: a retrospective study of interventions in one training practice. Br Med J. 1996;312(7034):819-821.
29. Sackett DL, Cook DJ. Can we learn anything from small trials? Ann N Y Acad Sci. 1993;703:25-31; discussion 31-2:25-31.
30. Jadad A. Types of randomised controlled trials. In: Randomised Controlled Trials. A User's Guide. Chapter 2. London: BMJ Books; 1998.
31. Jadad AR, Rennie D. The randomized controlled trial gets a middle-aged checkup. JAMA. 1998; 279(4):319-320.
32. Gould AL. Another view of active-controlled trials. Control Clin Trials. 1991;12(4):474-485.
33. Resch K. Pragmatic randomised controlled trials for complex therapies. Forsch Komplementarmed. 1998; 5 Suppl S1:136-139:136-139.
34. Abel U, Koch A. The role of randomization in clinical studies: myths and beliefs. J Clin Epidemiol. 1999;52(6):487-497.
35. Wilson GT. The clinical utility of randomized controlled trials. Int J Eat Disord. 1998;24(1):13-29.
36. Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C. Threats to applicability of randomised trials: exclusions and selective participation. J Health Serv Res Policy. 1999;4(2):112-121.
37. Herman J. Shortcomings of the randomized controlled trial: a view from the boondocks. J Eval Clin Pract. 1998;4(4):283-286.
38. Bottomley A. To randomise or not to randomise: methodological pitfalls of the RCT design in psychosocial intervention studies. Eur J Cancer Care. 1997; 6(3):222-230.
39. Vijan S, Kent DM, Hayward RA. Are randomized controlled trials sufficient evidence to guide clinical practice in type II (non-insulin-dependent) diabetes mellitus? Diabetologia. 2000;43(1):125-130.
40. Clarke GN. Improving the transition from basic efficacy research to effectiveness studies: methodological issues and procedures. J Consult Clin Psychol. 1995;63(5):718-725.
41. Wells KB. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry. 1999;156(1):5-10.
42. Hotopf M, Churchill R, Lewis G. Pragmatic randomised controlled trials in psychiatry. Br J Psychiatry. 1999;175:217-23.:217-223.
43. Hotopf M, Lewis G, Normand C. Putting trials on trial-the costs and consequences of small trials in depression: a systematic review of methodology. J Epidemiol Community Health. 1997;51(4):354-358.
44. Hilsden RJ, Verhoef MJ. Complementary and alternative medicine: evaluating its effectiveness in inflammatory bowel disease. Inflamm Bowel Dis. 1998;4(4):318-323.
45. Vickers A. A basic introduction to medical research. Part I: What is research and why do it? Complement Ther Nurs Midwifery. 1995;1(3):85-88.
46. Jacobson JS, Workman SB. Kronenberg F. Research on complementary and alternative therapies for cancer: issues and methodological considerations. J Am Med Womens Assoc. 1999;54(4):177-80, 183.
47. Walker LG, Anderson J. Testing complementary and alternative therapies within a research protocol. Eur J Cancer. 1999;35(11):1614-1618.
48. Rudolf MC, Lyth N, Bundle A, Rowland G, Kelly A, Bosson S et al. A search for the evidence supporting community paediatric practice. Arch Dis Child. 1999;80(3):257-261.
49. Geddes JR, Game D, Jenkins NE, Peterson LA, Pottinger GR, Sackett DL. What proportion of primary psychiatric interventions are based on evidence from randomised controlled trials? Qual Health Care. 1996;5(4):215-217.
50. Sackett DL, Wennberg JE. Choosing the best research design for each question. Br Med J. 1997; 20-27;315(7123):1636.
51. Vickers A, Cassileth B, Ernst E, Fisher P, Goldman P, Jonas W, et al. How should we research unconventional therapies? A panel report from the Conference on Complementary and Alternative Medicine Research Methodology, National Institutes of Health. Int J Technol Assess Health Care. 1997;13(1):111-121.
52. Vickers A. The NIH Methodology Conference: the methodology debate in the United Kingdom during the past ten years. J Altern Complement Med. 1995; 1(2):209-212.
53. Silverman WA, Chalmers I. Sir Austin Bradford Hill: an appreciation. Control Clin Trials. 1992;13(2): 100-105.
54. Moher D, Schulz KF, Altman DG, Lepage L. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357(9263):1191-1194.
55. White A, Ernst E. The case for uncontrolled clinical trials: a starting point for the evidence base for CAM. Complement Ther Med. 2001;9(2):111-116.
56. Guyatt G, Sackett D, Taylor DW, Chong J, Roberts R, Pugsley S. Determining optimal therapy-randomized trials in individual patients. N Engl J Med. 1986;314(14):889-892.
57. Cook DJ. Randomized trials in single subjects: the N of 1 study. Psychopharmacol Bull. 1996;32(3): 363-367.
58. Guyatt GH, Keller JL, Jaeschke R, Rosenbloom D, Adachi JD, Newhouse MT. The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience. Ann Intern Med. 1990;112(4):293-299.
59. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical Epidemiology: A Basic Science for Clinical Medicine. 2nd ed. New York, NY: Little, Brown & Company; 1991.
60. Ernst E, Resch KL. The "optional cross-over design" for randomized controlled trials. Fundam Clin Pharmacol. 1995;9(5):508-511.
61. Chadwick D. Monotherapy comparative trials: equivalence and differences in clinical trials. Epilepsy Res. 2001;45(1-3):101-103.
62. Chadwick D. Better comparisons of antiepileptic drugs: what measures of efficacy? Pharm World Sci. 1997;19(5):214-216.
63. Bero LA, Jadad AR. How consumers and policymakers can use systematic reviews for decision making. Ann Intern Med. 1997;127(1):37-42.
64. Jadad AR. Randomised Controlled Trials: A User's Guide. London, United Kingdom: BMJ Books; 1998.
65. Kemper KJ. Complementary and alternative medicine for children: does it work? Arch Dis Child. 2001;84(1):6-9.
66. Eisenberg DM, Kessler RC, Van Rompay MI, Kaptchuk TJ, Wilkey SA, Appel S, et al. Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann Intern Med. 2001; 135(5):344-351.
67. Astin JA. Why patients use alternative medicine: results of a national study. JAMA. 1998;279:1548-1553.
68. Kemper KJ. Holistic pediatrics = good medicine. Pediatrics. 2000;105(1 Pt 3):214-218.
69. Spigelblatt L, Laine-Ammara G, Pless IB, Guyver A. The use of alternative medicine by children. Pediatrics. 1994;94(6 Pt 1):811-814.
70. Simpson N, Pearch A, Finlay F, Lenton S. The use of complementary medicine in pediatric outpatient clinics. Ambulatory Child Health. 1998;3:351-356.
71. Ottolini M, Hamburger E, Loprieto J. Alternative Medicine Use Among Children in the Washington DC Area. San Francisco, CA: Pediatric Academic Societies; 1999.
72. Kelly KM, Jacobson JS, Kennedy DD, Braudt SM, Mallick M, Weiner MA. Use of unconventional therapies by children with cancer at an urban medical center. J Pediatr Hematol Oncol. 2000;22(5):412-416.